GlassScriptPhysician profile
Eric R Panahi
NPI 1619110830
$5,815.31
in general payments reported to CMS, 2019-2025
21 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $296 · 2021: $350 · 2022: $851 · 2023: $762 · 2024: $1,294 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,048.72 | 2020-2025 | Evenity, Prolia, Otezla |
| Janssen Biotech, INC. | $871.69 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $705.08 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $688.99 | 2020-2025 | Acthar |
| Ucb, INC. | $426.19 | 2023-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $419.81 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $412.51 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $294.77 | 2023-2025 | Tymlos |
| Abbvie INC. | $214.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.95 | 2024-2025 | Ofev |
| Aurinia Pharma U.S., INC. | $110.86 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $109.77 | 2019-2022 | |
| Lilly USA, LLC | $96.24 | 2025 | Zepbound, Taltz |
| Ani Pharmaceuticals, INC. | $54.42 | 2024-2025 | Purified Cortrophin Gel |
| Cumberland Pharmaceuticals, INC. | $51.59 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $43.68 | 2025 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $39.60 | 2022 | |
| Fidia Pharma USA INC. | $34.59 | 2019-2025 | Hymovis, Triluron |
| Alexion Pharmaceuticals, INC. | $27.29 | 2024 | Strensiq |
| Genzyme Corporation | $24.08 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $13.07 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Panahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.